GlassScriptPhysician profile
David A Merrill
NPI 1902923410
$2,190.96
in general payments reported to CMS, 2019-2025
27 companies · $305 in 2025
The $305 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $104 · 2021: $160 · 2022: $141 · 2023: $677 · 2024: $358 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,287 · Education: $51.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.17 |
| Education | $51.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $355.37 | 2019-2025 | Hizentra |
| Lilly USA, LLC | $267.56 | 2022-2025 | Amyvid, Kisunla |
| Ucb, INC. | $234.88 | 2023-2025 | Zilbrysq |
| Acadia Pharmaceuticals INC | $223.27 | 2019-2024 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $141.21 | 2019-2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $114.67 | 2019-2021 | |
| Lundbeck LLC | $114.07 | 2020-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $97.57 | 2023 | Ongentys, Ingrezza |
| Biogen, INC. | $89.93 | 2021-2025 | Leqembi |
| Argenx US, INC. | $55.97 | 2024 | Vyvgart Hytrulo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $51.78 | 2023 | Rexulti |
| Scilex Pharmaceuticals INC. | $49.46 | 2019 | |
| Mdd US Operations, LLC | $49.11 | 2024 | Gocovri |
| Alnylam Pharmaceuticals INC. | $47.71 | 2019-2020 | |
| Omniscient Neurotechnology America LTD | $46.29 | 2023 | Quicktome |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $41.64 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $29.80 | 2023 | Rexulti |
| Abbott Laboratories | $28.55 | 2022 | |
| Abbvie INC. | $27.71 | 2025 | |
| Grifols USA, LLC | $25.09 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $23.31 | 2025 | |
| Averitas Pharma INC. | $16.33 | 2023 | Qutenza |
| Acorda Therapeutics, INC | $15.98 | 2021 | |
| Allergan, INC. | $15.77 | 2020 | |
| Medtronic, INC. | $14.76 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.17 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Merrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.